Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Spero R. Cataland, Paul Coppo, Marie Scully, Bernhard Lämmle

Blood (2024) 144 (11): 1143–1152.

https://doi.org/10.1182/blood.2023022277

Published: 2024

Journal Articles

Plasmablastic lymphoma: better refine prognosis

Paul Coppo, Laure Ricard

Blood (2024) 143 (2): 101–102.

https://doi.org/10.1182/blood.2023022639

Published: 2024

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study

PAUL Coppo, Marie Scully, Johanna A. Kremer Hovinga, Maria Jose Aragon, Parth Patwari, Linda T. Wang, Bjorn Mellgard, Olulade Ayodele, Ragy Saad

Blood (2023) 142 (Supplement 1): 1261.

https://doi.org/10.1182/blood-2023-189181

Published: 2023

Journal Articles

Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study

PAUL Coppo, Marie Scully, Johanna A. Kremer Hovinga, Maria Jose Aragon, Parth Patwari, Linda T. Wang, Bjorn Mellgard, Olulade Ayodele, Ragy Saad

Blood (2023) 142 (Supplement 1): 4006.

https://doi.org/10.1182/blood-2023-189416

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

Adrien Picod, Jean-Michel Rebibou, Antoine Dossier, Bérengère Cador, David Ribes, Claire Vasco-Moynet, Caroline Stephan, Mathieu Bellal, Alain Wynckel, Pascale Poullin, Edwige Péju, Laure Ricard, Jean-Emmanuel Kahn, Raïda Bouzid, Ygal Benhamou, Bérangère Joly, Agnès Veyradier, Paul Coppo

Blood (2022) 139 (16): 2565–2569.

https://doi.org/10.1182/blood.2021015149

Published: 2022

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

Bogac Ercig, Nuno A. G. Graça, Kadri Kangro, Tom Arfman, Kanin Wichapong, Johana Hrdinová, Paul Kaijen, Floris P. J. van Alphen, Maartje van den Biggelaar, Karen Vanhoorelbeke, Agnès Veyradier, Paul Coppo, Chris Reutelingsperger, Gerry A. F. Nicolaes, Andres Männik, Jan Voorberg

Blood (2021) 137 (19): 2694–2698.

https://doi.org/10.1182/blood.2020007972

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

Effectiveness of Interactive Case-Based Online Education in Improving Attp Diagnosis and Treatment Selection

Christy Rohani-Montez, PhD, Dayan Gunesekera, Paul Coppo, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134292

Published: 2020

Journal Articles

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Blood (2020) 136 (3): 353–361.

https://doi.org/10.1182/blood.2019004221

Published: 2020

Includes: Supplemental data

Journal Articles

Immune TTP pathogenesis: the rising sun on HLA

Paul Coppo

Blood (2020) 135 (26): 2335–2336.

https://doi.org/10.1182/blood.2020006078

Published: 2020

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

NARROW

Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome

Plasmablastic lymphoma: better refine prognosis

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Pregnancy-Related Outcomes in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of a Retrospective Chart Review Study

Clinical Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Multinational Chart Review Study

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

N-glycan–mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP

Redefining outcomes in immune TTP: an international working group consensus report

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Effectiveness of Interactive Case-Based Online Education in Improving Attp Diagnosis and Treatment Selection

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Immune TTP pathogenesis: the rising sun on HLA

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only